NICE Issues Final Appraisal Determination Which Recommends Baraclude(R) As A Treatment Option For Eligible Chronic Hepatitis B Patients, UK
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
NICE (National Institute for Health and Clinical Excellence) has announced, in its Final Appraisal Determination (FAD), that Baraclude(R) (entecavir) is recommended as an option for treatment of eligible patients with chronic hepatitis B (CHB).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
